#News for #investors and #media: Today we announced a new licensing agreement with CureVac. This is our latest investment in vaccine platform technologies, allowing us to match the best platform to each pathogen and help prevent illness in more people around the world. Read more: https://gsk.to/4eOUVoJ
Exciting news, GSK! 🌍 Your new licensing agreement with CureVac marks a significant step in advancing vaccine platform technologies. This strategic move will enhance your ability to tailor solutions for different pathogens, ultimately helping to protect more people globally. Looking forward to the positive impact of this collaboration! #News #investors
Exciting news! Looking forward to seeing the impact of your new licensing agreement with CureVac in advancing vaccine technologies worldwide.
Exciting to see innovative collaborations like this!
Congratulations Any opportunity to past employers
Great news!
Congratulations!!
Great news Lenny. Tell us more…
Keep growing!GSK
CEO at EM Biotech | Managing Director at ROSCUE Therapeutics | Board Chairman at QUANTRO Therapeutics
1moCongrats to the GSK and CureVac teams to getting this deal done and all the best going forward!